Inside the research
The Cooper Companies, Inc.
COO Research profile · latest available data
Price overview
$55.38
· +0.00 (+0.0%)
| 52w hi | $84.32 |
|---|---|
| 52w lo | $53.27 |
| Vol | 4.45M |
| As of | 25 Sep 2026 |
The Verdict
Our score -0.19
| Short | -0.54 |
|---|---|
| Medium | -0.09 |
| Long | +0.35 |
computed 2026-09-27
Key fundamentals
The Cooper Companies, Inc.
Healthcare · Medical Instruments & Supplies
| Market cap | $10.53B |
|---|---|
| Enterprise value | $13.18B |
| Trailing P/E | 19.03x |
| Forward P/E | 11.80x |
| EV / EBITDA | 14.14x |
| P / S (ttm) | 2.49x |
| Profit margin | 13.5% |
| Return on equity | 6.8% |
| Revenue growth | +0.6% |
| Earnings growth | +357.1% |
| Debt / equity | 33.63 |
Layer Breakdown
| Layer | Raw | Contribution |
|---|---|---|
| Fundamental | +0.34 | |
| Sector | +0.08 | |
| Technical | -0.36 | |
| Earnings | +0.00 | |
| Sentiment | +0.00 |
macro × 1.00 · 2026-09-27
Business overview
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.
Risk Metrics
| Beta vs SPX | 0.71 |
|---|---|
| Corr SPX | 0.34 |
| Annual vol | 33.2% |
| Annual ret | -28.9% |
| Sharpe | -0.87 |
| Max DD | -51.7% |
Window: 504 trading days (504 obs)
Analyst Coverage
| Mean PT | $91.07 |
|---|---|
| High / Low | $103.00 / $69.00 |
| Median | $95.00 |
| Analysts | 15 |
| Strong Buy | 5 | |
|---|---|---|
| Buy | 6 | |
| Hold | 5 | |
| Sell | 1 | |
| Strong Sell | 0 |
Recent rating actions
| 2026-03-06 | Needham | → Buy |
| 2026-03-06 | Citigroup | → Neutral |
| 2026-03-06 | Barclays | → Overweight |
| 2026-02-03 | Needham | → Buy |
| 2026-01-26 | Barclays | → Overweight |
| 2025-12-08 | Morgan Stanley | → Equal-Weight |
Material Events
| Date | Event | 8-K |
|---|---|---|
| 2026-06-04 | Earnings Release, Other Material Event… | read |
| 2026-05-04 | Officer / Director Change | read |
| 2026-04-08 | Shareholder Vote | read |
| 2026-03-05 | Earnings Release, Exhibits | read |
| 2026-02-04 | Material Agreement, Exhibits | read |
| 2025-12-23 | Material Agreement, Officer / Director Change… | read |
| 2025-12-12 | Officer / Director Change | read |
| 2025-12-04 | Earnings Release, Officer / Director Change… | read |
| 2025-08-27 | Earnings Release, Exhibits | read |
| 2025-05-29 | Earnings Release, Exhibits | read |
| 2025-04-30 | Officer / Director Change | read |
| 2025-04-02 | Shareholder Vote | read |
Insider Trades
| Date | Insider | Role | Action | Shares | Value |
|---|---|---|---|---|---|
| 2026-04-01 | Rosebrough Walter M Jr | Director | Option exercise | 832 | — |
| 2026-04-01 | WEISS ROBERT S | Director | Option exercise | 3.65K | — |
| 2026-04-01 | Rivas Maria | Director | Option exercise | 3.32K | — |
| 2026-04-01 | Jay Colleen | Director | Option exercise | 3.32K | — |
| 2026-04-01 | Carbone Barbara | Director | Option exercise | 3.05K | — |
| 2026-04-01 | MADDEN TERESA S | Director | Option exercise | 3.32K | — |
| 2026-04-01 | Lucchese Cynthia L | Director | Option exercise | 3.32K | — |
| 2026-04-01 | Kurzius Lawrence Erik | Director | Option exercise | 3.32K | — |
Flow & Concentration
| Insider 180d net | $0 |
|---|---|
| Insider buys / sells | 0 / 0 |
| Insider bias | Neutral |
| 13F holders | 0 |
| Top-5 share | 0.0% |
| HHI | 0 (—) |
Dividends
| Yield (TTM) | 0.00% |
|---|---|
| $ / share (TTM) | $0.00 |
| 5y CAGR | +0.0% |
Annual dividend per share
| 2018 | $0.01 |
|---|---|
| 2019 | $0.01 |
| 2020 | $0.01 |
| 2021 | $0.01 |
| 2022 | $0.01 |
| 2023 | $0.01 |
SEC Filings
The Long Run
FY 2010–2025 · 16 years
| Line | Latest | CAGR | Trend |
|---|---|---|---|
| Revenue | $4.09B | +9.5% | |
| Gross profit | $2.36B | +8.7% | |
| Operating income | $682.90M | +8.9% | |
| Net income | $294.20M | +10.7% | |
| Cash from ops | $607.50M | +5.6% |
Indices
Recent Sessions
| Date | Open | High | Low | Close | Vol |
|---|---|---|---|---|---|
| Sep 25 | $55.18 | $56.18 | $55.02 | $55.38 | 4.45M |
| Sep 24 | $56.06 | $56.64 | $54.85 | $55.38 | 6.25M |
| Sep 23 | $55.13 | $56.08 | $54.56 | $56.07 | 4.14M |
| Sep 22 | $54.21 | $55.49 | $54.08 | $55.29 | 2.69M |
| Sep 21 | $55.13 | $55.53 | $54.10 | $54.12 | 4.19M |
Understand the score. Research layers are inputs to a model, and the available data has limits.
Read the methodology →